Effect of Hepatitis C Virus and Its Treatment on Survival

被引:71
作者
Butt, Adeel A. [1 ,2 ,3 ]
Wang, Xiaoqiang [2 ]
Moore, Charity G. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] Vet Adm VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[3] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA
基金
美国国家卫生研究院;
关键词
HEPATOCELLULAR-CARCINOMA; UNITED-STATES; PEGINTERFERON ALPHA-2A; PLUS RIBAVIRIN; INFECTION; CIRRHOSIS; HIV; HCV; VETERANS; THERAPY;
D O I
10.1002/hep.23000
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV-infected veterans and uninfected controls. We used a national sample of HCV-infected persons and HCV-uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV-infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan-Meier survival plots were generated to determine and compare survival among HCV-infected and HCV-uninfected persons, and among treated and untreated HCV-infected persons.(-) We identified 34,480 matched pairs of HCV-infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31-1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV-infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27-0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0-23 weeks and 24-47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009;50:387-392.)
引用
收藏
页码:387 / 392
页数:6
相关论文
共 29 条
[1]  
Backus LI, 2005, JAIDS-J ACQ IMM DEF, V39, P613
[2]  
Batty DS, 2001, AM J TRANSPLANT, V1, P179, DOI 10.1034/j.1600-6143.2001.10213.x
[3]  
Brunetto MR, 1998, LANCET, V351, P1535
[4]   Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans [J].
Butt, A. A. ;
Khan, U. A. ;
McGinnis, K. A. ;
Skanderson, M. ;
Kwoh, C. Kent .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (12) :890-896
[5]   Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis [J].
Butt, A. A. ;
Skanderson, M. ;
McGinnis, K. A. ;
Ahuja, T. ;
Bryce, C. L. ;
Barnato, A. E. ;
Chang, C.-C. H. .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (10) :688-696
[6]   Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects [J].
Butt, A. A. ;
Justice, A. C. ;
Skanderson, M. ;
Good, C. ;
Kwoh, C. K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (04) :585-591
[7]   Comorbidities and their impact on mortality in HCV and HCV-HIV-coinfected persons on dialysis [J].
Butt, Adeel A. ;
Khan, Uzma A. ;
Skanderson, Melissa .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (09) :1054-1059
[8]   Rate and predictors of treatment prescription for hepatitis C [J].
Butt, Adeel A. ;
Justice, Amy C. ;
Skanderson, Melissa ;
Rigsby, Michael O. ;
Good, Chester B. ;
Kwoh, C. Kent .
GUT, 2007, 56 (03) :385-389
[9]  
Butt Adeel A, 2005, Expert Rev Anti Infect Ther, V3, P241, DOI 10.1586/14787210.3.2.241
[10]   Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV [J].
Campos, Nicole G. ;
Salomon, Joshua A. ;
Servoss, Julie C. ;
Nunes, David P. ;
Samet, Jeffrey H. ;
Freedberg, Kenneth A. ;
Goldie, Sue J. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (03) :272-279